1 / 24

Pediatric urinary tract infection

Pediatric urinary tract infection. Scott Weissman, MD Fellows’ orientation 7 July 2010. Pediatric UTI by age. Non-toilet-trained children (NTTC) Newborn/infants (up to 60 d) Present with non-specific signs/symptoms Managed by ‘rule out sepsis’ guideline Toddlers (up to 2-3 yr)

chiku
Download Presentation

Pediatric urinary tract infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric urinary tract infection Scott Weissman, MD Fellows’ orientation 7 July 2010

  2. Pediatric UTI by age • Non-toilet-trained children (NTTC) • Newborn/infants (up to 60 d) • Present with non-specific signs/symptoms • Managed by ‘rule out sepsis’ guideline • Toddlers (up to 2-3 yr) • Unable to express themselves well • Present with fever, abd pain, vomiting/diarrhea • Toilet-trained children (TTC) • Pre/school-age (up to 12 yr) • Can describe/localize sx • Present like adults: dysuria, frequency • Adolescent (13 yr and older) • Potentially sexually active

  3. New recommendations: Diagnosis • Diagnose UTI in NTTC via high quality urine specimen (ie, not a bag) • Catheter • Suprapubic tap • In adolescents, document external GU exam and test for GC/Chlamydia • Nucleic acid amplification tests; send-out to UW • NOT clean catch or midstream - collect first 20 cc

  4. New Recommendations: Empiric Rx • When to start empiric therapy • In NTTC – for clinical suspicion • In TTC – for clinical findings plus (+) UA/urine dip/microscopy • What to start • Newborns (0-30 d) • IV amp + gent • Infants (over 30 d): • IV ceftriaxoneif admit; IV amp + gent if suspect E-coccus • Infants (30-60 d) not admitted: • IM ceftriaxone • Older children (over 60 d): • PO cephalexin; if CS allergy, PO Bactrim • IM ceftriaxone

  5. New Recommendations: Empiric Rx • Length of therapy • Newborn (0-30 d): 7 d IV followed by 7 d PO • Infant (31-60 d): IV until afebrile x 24 h and BCx (-) x 36 h, followed by PO to complete 14 d • Adolescents: 3 d PO

  6. Antibiotic Resistance

  7. PBLR Enterobacteriaceae Seattle Children’s 1999-2009 # isolates Year

  8. chromosome plasmid active ampC inactive ampC AmpC enzymes are encoded on chromosomes and plasmids SPICEM Serratia, Providencia, indole-positive Proteus, Citrobacter, Enterobacter, Morganella E. coli Salmonella

  9. Etiologic agents and Resistance

  10. aac(3)-II TEM-1 OXA-1 tetA aac(6’)-Ib CTX-M-15 Emerging Resistance • Escherichia coli • Class A enzyme CTX-M-15 associated with emerging clone ST 131 (serotype O25:H4) • Class C enzyme CMY-2 associated with multiple clones (and multiple species, e.g., Salmonella Typhimurium) Multidrug resistance region of plasmid pC15-1a, carried by widely-disseminated E. coli clone ST131.

  11. Ciprofloxacin • Toxicity concerns re damage to cartilage in multiple juvenile animal models • Record of safety in Europe, in cystic fibrosis • Per AAP, increasing resistance is a growing concern • Clinical indications • UTI caused by P. aeruginosaor other multidrug-resistant gram-negative bacteria (per AAP) • Complicated E. coli UTI and pyelonephritis attributable to E. coli in pts 1-17 yrs of age (per FDA) • Patient/family counseling • “If use of an FQ is recommended for a patient younger than 18 y/o, the risks and benefits should be explained to the pts and parents” (AAP Red Book, 2006)

  12. Fosfomycin • Bactericidal PO antibiotic with one-time dosing that inhibits bacterial cell wall synthesis • Inactivates pyruvyl transferase – first committed step in cell wall synthesis • High urinary levels > 48 h • 90% of SCH ESBL-producing E. coli susceptible • Approved for >12 yr • Powder form, comes in sachet, dissolved in water • Not on SCH formulary but available in community • Adverse reactions: headache, diarrhea, nausea, vaginitis

  13. Cefixime • PO third-generation cephalosporin with once-daily dosing (dose amount doubled on day one) • Not for use in infants less than 3 months of age • Suspension contain sodium benzoate (metabolite of benzyl alcohol) • Large amounts of benzyl alcohol associated with fatal toxicity in newborns: ‘gasping syndrome’ • Metabolic acidosis, resp distress, gasping • CNS dysfunction (sz, ICH) • Hypotension, cardiovascular collapse • Benzoate displaces bilirubin from protein

  14. New Recommendations: Imaging • Paradigm shift: Reduction in use of VCUG for initial imaging in children with first-time UTI • Infants and non-toilet-trained children • Renal ultrasound OR high-quality 3rd trimester US read as normal • VCUG only if atypical UTI - one of the following: • Seriously ill • Poor urine flow • Abdominal or bladder mass • Elevated creatinine • Septicemia • Failure to respond to appropriate rx within 48 h • Infection caused by organism other than E. coli • DMSA scan 12 months after atypical UTI

  15. New Recommendations: Imaging • Toilet-trained children and adolescents • Renal ultrasound for boys with first UTI and for girls with atypical UTI • If VUR found, prophylactic antibiotics given

  16. Underlying pathophysiology • Vesicoureteral reflux (VUR) • Up to 35% of children w/UTI under age 12 • Highest in 1 y/o (50%) • Posterior urethral valves (boys) • May be missed at birth • Ask parents about voiding stream • Dysfunctional voiding (girls) • Recurrent cystitis common • Voiding history is useful

  17. Antibiotic prophylaxis in VUR • Historically, pts w/documented VUR of any grade have been rx’d prophylactically • TMP/SMX, TMP only, SMX only • Nitrofurantoin • Based on data from poorly-controlled studies and biological assumptions • Chronic prophylactic abx reduce risk of UTI • Prevention of UTI will prevent renal scarring

  18. Antibiotic prophylaxis in VUR • Cochrane Review finds significant lack in evidence supporting these assumptions, need for methodologically-sound studies (see Williams et al) • RIVUR (Randomized Intervention for children with VesicoUreteral Reflux) study announced 2/08 • Multicenter, double-blind, randomized, placebo-controlled trial, to enroll 600 children 2-72 mos with grades I-IV VUR, to receive TMP/SMX or placebo • Collaboration of 15 clinical trial centers throughout N.A., data coordinated at UNC • Increasing use of cystoscopic Deflux (hyaluronic acid gel) injection at vesicoureteral junction

  19. References Committee on Infectious Diseases (2006) Pediatrics 118:1287-1292. Committee on Quality Improvement, Subcommittee on Urinary Tract Infection (1999) Pediatrics 103:843-52. Cooper CS et al (2000) J Urol 163:269-73. DeMuri GP & ER Wald (2008) PIDJ 27:553-4. Garin EH et al (2006) Pediatrics 117:626-32. Greenfield SP et al (2008) J Urol179:405-7. Lavollay M et al (2006) AAC 50:2433-8. Reddy PP (1997) Pediatrics 100:555-6. Robicsek A et al (2006) Nat Med 12:83-8. Williams G et al (2006) Cochrane Database Syst Rev 3:CD001534.

More Related